ClinVar Miner

Submissions for variant NM_002317.7(LOX):c.1021A>C (p.Thr341Pro)

dbSNP: rs1436353084
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Center for Medical Genetics Ghent, University of Ghent RCV001530398 SCV001468319 likely pathogenic Cutis laxa; Generalized arterial tortuosity 2021-01-05 criteria provided, single submitter clinical testing Several lines of evidence support the pathogenicity of the LOX variants in the patients’ phenotype. Firstly, the mutation is located in the catalytic domain, absent in control databases and predicted deleterious by all in silico prediction algorithms including Polyphen2, SIFT, Provean and Mutation Taster. Secondly, Lysyl oxidase directly interacts with Fibulin-4 (EFEMP2), the protein deficient in ARCL1B, with similar clinical effects on the vasculature, skin (cutis laxa), skeleton and respiratory system (including diaphragmatic abnormalities). Thirdly, several LOX knockout mouse models (Lox-/-) have been generated that presented with a very similar clinical phenotype to that seen in our patients. Fourthly, the ultrastructural findings can be interpreted as showing a significant fault in elastogenesis; the microfibrillar scaffolding of the elastic fibre is forming but the actual assembly of elastin in its interstices is minimal, all of which is consistent with a lysyl oxidase anomaly 6.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.